News from janssen pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 24, 2016, 08:00 ET U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes

Janssen Pharmaceuticals, Inc. (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved INVOKAMET®, a fixed-dose...


May 16, 2016, 08:00 ET Newly Published Real-World Evidence Shows Adults with Type 2 Diabetes Significantly Improve Blood Glucose Control and Achieve Treatment Goals When Using INVOKANA® (canagliflozin)

Results from three separate data analyses representing diverse patient populations from real-world clinical practice show that use of the...


May 12, 2016, 08:18 ET Janssen Announces 15 Key Research Presentations at Annual Meeting of the American Psychiatric Association

 The Janssen Pharmaceutical Companies announced that several posters related to Janssen's work in mental health will be featured at the 169th...


Mar 21, 2016, 08:19 ET Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 14 Presentations at American College of Cardiology's 65th Annual Scientific Session

Janssen Pharmaceuticals, Inc., and its development partner, Bayer, today announced that 14 data presentations will be presented at the American...


Mar 14, 2016, 08:00 ET First Real-World Evidence Comparing an SGLT2 Inhibitor with DPP-4 Inhibitors Shows Adults with Type 2 Diabetes Achieve Greater Blood Glucose Control with INVOKANA® (canagliflozin)

Results of a new analysis of data from real-world clinical practice show that, in adults with type 2 diabetes, use of the once-daily oral...


Dec 18, 2015, 16:00 ET Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections

New approach for early treatment and interception of HPV-induced cancers   Janssen Pharmaceuticals, Inc. (Janssen) announced today that the...


Dec 07, 2015, 18:36 ET Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the results from their real-world study...


Dec 07, 2015, 07:00 ET First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer

 Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the first results from CALLISTO, a...


Nov 18, 2015, 17:05 ET New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Infection

- ALS-008176 now being evaluated in RSV-infected infants - Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that...


Nov 13, 2015, 08:00 ET Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance

In recognition of National Family Caregivers Month, Janssen Pharmaceuticals, Inc. today announced results of "A Large-Scale Survey of Caregivers of...


Nov 09, 2015, 07:00 ET Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has obtained worldwide rights, excluding China and Korea, to develop and...


Nov 06, 2015, 16:16 ET Important Global Data from XARELTO® EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced that 17 data presentations,...


Sep 15, 2015, 08:31 ET Janssen Initiates FIRST, a Novel Study to Evaluate the Benefit of Caregiver Education in Improvement of Outcomes for Patients with Serious Mental Illness

 Today, Janssen Pharmaceuticals, Inc. announced the initiation of the FIRST (Family Intervention in Recent Onset Schizophrenia Treatment) study...


Sep 01, 2015, 07:01 ET New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO®

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety...


Jun 25, 2015, 08:57 ET INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available

The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in...


May 28, 2015, 08:30 ET New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

 Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new...


May 19, 2015, 16:05 ET Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered...


May 19, 2015, 08:17 ET U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

 There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only...


May 18, 2015, 08:30 ET New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA® (canagliflozin)

 Janssen Pharmaceuticals, Inc. (Janssen) today announced results from three real-world analyses, which found significant improvements in blood...


May 15, 2015, 08:00 ET Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients

New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial...


May 14, 2015, 14:46 ET New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

 Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced results from the VENTURE-AF trial. The study...


May 11, 2015, 17:47 ET U.S. FDA Issues Complete Response Letter to sNDA Seeking to Expand the Label for INVEGA SUSTENNA®

Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response...


May 11, 2015, 08:00 ET Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV

 Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of...


Apr 28, 2015, 08:00 ET Janssen lanza iniciativa en la comunidad hispana en EE. UU. para ayudar a mejorar el cuidado de la diabetes tipo 2

Janssen Pharmaceuticals, Inc., fabricante de INVOKANA® (canagliflozina) para el tratamiento de la diabetes tipo 2, anunció hoy el...


Apr 28, 2015, 08:00 ET Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care

 Janssen Pharmaceuticals, Inc., the manufacturer of INVOKANA® (canagliflozin) for the treatment of type 2 diabetes, today announced the...